In vivo Pharmacokinetics

We provide in vivo pharmacokinetic studies using wide range of administration routes.

Our pharmacokinetic (PK) studies in rats, mice and dogs help in understanding the characteristics of New Chemical entities (NCEs). Our PK studies are highly efficient in predicting the exposure while determining the dosage levels and frequencies for testing in preclinical in vivo animal disease efficacy models. We conduct PK studies for small and large molecules at our state-of-the-art laboratories and vivarium. Our DMPK scientists help understand the drug's AUC, clearance, half-life, the volume of distribution, Cmax, and Cmin in the body over time.

Industry’s leading CRO for Pharmacokinetic Studies A variety of surgical animal PK models Track record of delivering 200+ GLP studies GLP accredited bioanalysis labs for PK studiesNon-GLP bioanalysis facilities for PK studiesA wide range of administration routes

Speak to our experts

PK in Rodents (rats/ mice)

Single/ Multiple dose
Discrete/ Cassette
Micro sampling
Cross-over/ Non-cross-over design
Dose escalation studies
Food effect, Gender effect

Surgical models (Cannulations)

Single or double Jugular vein
Tail vein
Duodenum
Bile duct
Femoral vein

PK in other Matrices (Rodents)

Issue distribution
Brain penetration
PK in CSF, Spinal cord, Sciatic nerve
Testes PK
Excretion studies

PK in Beagle Dogs

Single/ multiple dose PK
Non-terminal studies

Route of administration

Oral
Intravenous (IV)
Intramuscular (IM)
Subcutaneous (SC)
Intraperitoneal (IP)
Dermal

Why Aurigene Pharmaceutical Services?

Variety of surgical animal PK models

Track record of delivering 200+ GLP studies

GLP accredited bioanalysis labs for PK studies

Non-GLP bioanalysis facilities for PK studies

A wide range of administration routes

Other Services

GLP and Non-GLP Bioanalysis

PAMPA Assay

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

Page name

page url

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

I agree to receive updates from Aurigene

* I agree and accept the Privacy Policy and Terms of Use of this website.

Resources

JULY 02, 2026

The Journey from Scientific to patient impact

Home › Company › Aurigene 360°: The Journey from Scientific Insight to Patient Impact Publish on : January 25, 2026 Shares: Every medicine begins with a question. Sometimes with a scientist studying a protein structure late at night. Sometimes with a disease that still has no effective treatment. Sometimes with a ...

JUNE 12, 2026

The Journey from Scientific Insight to Patient Impact
Read More
FEBRUARY 25, 2025

Transforming Drug Discovery with Aurigene.AI
Read More
OCTOBER 01, 2024

PROTACs: Research for a life without cancer
Read More

View All

Advancement in personalized medicine and how the CRDMO industry is part of the solution

Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...

View All

Cell Line Development

We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...

View All

End-to-End Rebuild of a Complex Bicyclic Peptide Synthesis

...

View All

Identification of Degradants of Thermal and Oxidation Stress Studies of Empagliflozin and Linagliptin Tablets by HPLC-PDA and LC-MS Instrumental Techniques

2022

Objective of the manuscript is to identify the degradants observed in the thermal and oxidation degradation sample of Empagliflozin and Linagliptin tablets by using LC-MS and HPLC-PDA instrumental techniques. Thermal and oxidation degradation samples were injected in HPLC-PDA and LC-MS instruments. Mass of the degradants were detected by LC-MS technique, ...

Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.

2005

Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation

2005

The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones

2005

A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More

View All

Frequently asked questions

What are some common challenges faced during in vivo pharmacokinetics (PK) studies?

Some major challenges during in vivo pharmacokinetic (PK) studies are optimization of new drug entities for their appropriate ADME studies and improper in vitro analysis giving inaccurate results. In addition, inaccuracies in tissue biopsy analysis can pose challenges, which can lead to erroneous data on tissue drug distribution during PK studies. The other critical challenges include the safety and efficacy of the drug that can affect patient response as well as physiological and pathological processes, influencing the PK studies.

How are in vivo pharmacokinetics studies conducted in Aurigene Pharmaceutical Services?

At Aurigene, we efficiently perform the PK studies corresponding to preclinical in vivo testing using animal modalities. With the state-of-the-art infrastructure and GLP- accredited bioanalysis laboratories, PK studies of the potential drug are conducted through characterization procedures and ADME parameters. The exposure, dosage levels, and preclinical testing are conducted via blood and urine samples depending upon the single or repeated dose. A wide range of administration routes are studied to optimize the drug dosage and drug delivery. The various other pharmacokinetic services include half-life determination, volume of distribution analysis, and drug clearance assessment.

How are dog PK studies conducted in Aurigene Pharmaceutical Services?

At Aurigene, in vivo PK studies are conducted on rats, mice, and beagle dogs. These studies provide a deeper understanding of the pharmacological profile and action of potential new chemical entities or candidate drugs. The PK studies involve the validation and assessment in terms of exposure limits, dosage level, frequency, bioavailability and multidose safety studies in beagle dogs for the preclinical testing. Our in vivo PK studies in dogs are highly efficient in predicting the exposure while determining the dosage levels and frequencies for preclinical testing.

How are pharmacokinetic parameters calculated in dog PK studies in Aurigene Pharmaceutical Services?

Pharmacokinetic studies in animals involve the assessment and validation of the critical parameters on ADME studies. It substantiates the collective data regarding the clearance studies, half-life, bio availability, volume of distribution, and protein drug interactions. The in vivo PK studies in dogs, rats, and mice provide valuable insights into the characteristic nature of new chemical entities (NCEs). At Aurigene, PK studies conducted are highly efficient in determining exposure and dosage levels and frequencies in preclinical testing for in vivo animal disease efficacy models.

Does APSL perform analytical method development in order to ensure that the analytical method is “stability-indicating”?

Stability indicating nature of analytical method will be demonstrated during analytical method development of drug substance related substances and assay method. To demonstrate the stability indicating nature of analytical method, degradation samples shall be generated by stressing the test sample with acid, base, water hydrolysis, oxidative, thermal and photostability study . The degraded sample shall be analyzed and demonstrated the separation of degradation impurities from known impurities and analyte peak. Photostability study shall be carried out as per ICH QIB.

What are the different types of in vivo pharmacokinetics studies conducted in Aurigene Pharmaceutical Services?

PK studies determine the exposure and dosage levels and frequencies for testing in preclinical in vivo animal disease efficacy models. At Aurigene, PK services are offered using advanced technological expertise. We conduct PK studies for small and large molecules in the laboratories and vivarium. We measure pharmacokinetic parameters such as area under the curve (AUC), drug clearance, half-life, volume of distribution, maximum concentration (C_max), and minimum concentration (C_min) in the body over time.

Further, at Aurigene, pharmacokinetic studies are conducted in rodents or mice using single or multiple doses. Micro-sampling, dose escalation studies, tissue distribution, brain penetration, pharmacokinetic studies in the spinal cord and CSF, and excretion studies are also performed.

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

Proceed Back

In vivo Pharmacokinetics

PK in Rodents (rats/ mice)

Surgical models (Cannulations)

PK in other Matrices (Rodents)

PK in Beagle Dogs

Route of administration

Why Aurigene Pharmaceutical Services?

Other Services

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

section

rightCaptcha

Resources

The Journey from Scientific to patient impact

End-to-End Rebuild of a Complex Bicyclic Peptide Synthesis

Identification of Degradants of Thermal and Oxidation Stress Studies of Empagliflozin and Linagliptin Tablets by HPLC-PDA and LC-MS Instrumental Techniques

Frequently asked questions

What are some common challenges faced during in vivo pharmacokinetics (PK) studies?

How are in vivo pharmacokinetics studies conducted in Aurigene Pharmaceutical Services?

How are dog PK studies conducted in Aurigene Pharmaceutical Services?

How are pharmacokinetic parameters calculated in dog PK studies in Aurigene Pharmaceutical Services?

Does APSL perform analytical method development in order to ensure that the analytical method is “stability-indicating”?

What are the different types of in vivo pharmacokinetics studies conducted in Aurigene Pharmaceutical Services?

Leaving already?

Don't forget to join us at

CPHI Worldwide 2023.